GBT Announces New Employment Inducement Grants
June 03 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced
that on June 1, 2020, the compensation committee of GBT’s board of
directors granted seven new employees restricted stock units for an
aggregate of 34,000 shares of the company’s common stock. These
awards were made under GBT’s Amended and Restated 2017 Inducement
Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The 2017 Inducement Equity Plan
was adopted by GBT’s board of directors in January 2017 and has
been amended and restated from time to time.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to the
discovery, development and delivery of life-changing treatments
that provide hope to underserved patient communities. Founded in
2011, GBT is delivering on its goal to transform the treatment and
care of sickle cell disease (SCD), a lifelong, devastating
inherited blood disorder. The company has introduced Oxbryta®
(voxelotor), the first FDA-approved treatment that directly
inhibits sickle hemoglobin polymerization, an underlying cause of
SCD. GBT is also advancing its pipeline program in SCD with
inclacumab, a p-selectin inhibitor in development to address pain
crises associated with the disease. In addition, GBT’s drug
discovery teams are working on new targets to develop the next
generation of treatments for SCD. To learn more, please visit
www.gbt.com and follow the company on Twitter @GBT_news.
Contact Information:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Stephanie Yao (investors)650-741-7730syao@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024